Investors

Investor Overview

Organovo is a pioneer in the development of human primary cell 3-D bioprinted tissues. The primary effort to develop a human therapeutic liver tissue candidate was halted and the company restructured to focus on utilizing its tissues for disease modeling and drug discovery, with the therapeutic liver tissue development on hold pending additional advances. 

2018 Annual Report
Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

© 2020 Organovo Holdings, Inc. 6275 Nancy Ridge Drive, Suite 110 San Diego, CA 92121